U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07542067) titled 'Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton's Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment' on May 20, 2025.
Brief Summary: Progressive SSc is an entity with limited therapeutic alternatives and a survival rate of less than 45% within the first 3 to 5 years. The disease causes severe limitations in quality of life, ranging from functional impairment to depression. Up to 20% of patients become refractory to conventional treatment with disease-modifying anti-rheumatic drugs (DMARDs) and cyclophosphamide therapy. This condition favors progression ...